Casi pharmaceuticals, inc. reports unaudited consolidated financial results for the third quarter and nine months ended september 30, 2019

Casi pharmaceuticals, inc. reported unaudited consolidated financial results for the third quarter and nine months ended september 30, 2019. for the quarter, the company announced total revenues of $2,787,000. loss from operations was $10,642,000 compared to $8,711,000 a year ago. net loss was $9,669,000 compared to $8,756,000 a year ago. basic and diluted net loss per share was $0.10 compared to $0.10 a year ago. for the nine months, the company announced total revenues of $2,787,000. loss from operations was $34,777,000 compared to $18,170,000 a year ago. net loss was $33,080,000 compared to $18,207,000 a year ago. basic and diluted net loss per share was $0.35 compared to $0.22 a year ago.
CASI Ratings Summary
CASI Quant Ranking